---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063975"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:53:03.132882+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q1 net loss $51.7M; on track for Phase 3 atacicept results in 2Q 2025

## Summary
- Net loss of $51.7M ($0.81/share) vs $28.4M ($0.56/share) same quarter last year.
- Cash, equivalents and marketable securities of $589.8M as of March 31, 2025.
- Primary endpoint results from atacicept pivotal Phase 3 ORIGIN trial in IgAN expected in 2Q 2025.
- BLA submission for atacicept accelerated approval planned for 4Q 2025; potential launch in 2026.
- Expanded atacicept program into primary membranous nephropathy, FSGS, and minimal change disease.

## SEC filing metadata
- accession: 0000950170-25-063975
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/0000950170-25-063975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063975
- JSON: https://secwatch.observer/filing/0000950170-25-063975.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.